Should I buy or sell Poseida Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Poseida Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PSTX shares. View PSTX analyst ratings or view top-rated stocks .

What is Poseida Therapeutics' stock price target for 2024?

3 Wall Street research analysts have issued 12 month price targets for Poseida Therapeutics' stock. Their PSTX share price targets range from $10.00 to $20.00. On average, they expect the company's stock price to reach $14.67 in the next year. This suggests a possible upside of 626.1% from the stock's current price. View analysts price targets for PSTX or view top-rated stocks among Wall Street analysts .

How have PSTX shares performed in 2024?

Poseida Therapeutics' stock was trading at $3.36 at the beginning of 2024. Since then, PSTX stock has decreased by 39.9% and is now trading at $2.02. View the best growth stocks for 2024 here .

When is Poseida Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our PSTX earnings forecast .

How were Poseida Therapeutics' earnings last quarter?

Poseida Therapeutics, Inc. (NASDAQ:PSTX) released its earnings results on Thursday, March, 7th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.09. The firm earned $25 million during the quarter, compared to the consensus estimate of $12.50 million. Poseida Therapeutics had a negative trailing twelve-month return on equity of 94.90% and a negative net margin of 190.76%.

What ETFs hold Poseida Therapeutics' stock?

ETFs with the largest weight of Poseida Therapeutics (NASDAQ:PSTX) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA) . Global X Genomics & Biotechnology ETF (GNOM) .

What other stocks do shareholders of Poseida Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Poseida Therapeutics investors own include Moderna (MRNA) , Advanced Micro Devices (AMD) , AngloGold Ashanti (AU) , Micron Technology (MU) , Eaton (ETN) , Corning (GLW) , OPKO Health (OPK) , Overstock.com (OSTK) , Sorrento Therapeutics (SRNE) and SSR Mining (SSRM) .

When did Poseida Therapeutics IPO?

Poseida Therapeutics (PSTX) raised $150 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. BofA Securities, Piper Sandler and William Blair acted as the underwriters for the IPO.

How do I buy shares of Poseida Therapeutics?

Shares of PSTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PSTX

Poseida Therapeutics (PSTX) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free PSTX Stock Alerts

$2.02

+0.02 (+1.00%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.95
▼
$2.07
50-Day Range: $2.00
▼
$4.13
52-Week Range: $1.54
▼
$4.27

Volume: 641,417 shs
Average Volume: 712,730 shs
Market Capitalization: $194.91 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.67

Get Poseida Therapeutics alerts:

Poseida Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 626.1% Upside
$14.67 Price Target
Short Interest: Bearish
6.70% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.93
Upright™ Environmental Score
News Sentiment: -0.05
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.77) to ($1.92) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.97 out of 5 stars

Medical Sector

368th out of 911 stocks

Biological Products, Except Diagnostic Industry

50th out of 150 stocks

3.5

Analyst's Opinion

Consensus Rating
Poseida Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Poseida Therapeutics has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.70% of the float of Poseida Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Poseida Therapeutics has a short interest ratio ("days to cover") of 5.7.
Change versus previous month
Short interest in Poseida Therapeutics has recently increased by 7.29%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Poseida Therapeutics does not currently pay a dividend.
Dividend Growth
Poseida Therapeutics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Poseida Therapeutics has received a 73.00% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Poseida Therapeutics is -0.93.

1.1

News and Social Media Coverage

News Sentiment
Poseida Therapeutics has a news sentiment score of -0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Poseida Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 4 people have searched for PSTX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Poseida Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.10% of the stock of Poseida Therapeutics is held by insiders.
Percentage Held by Institutions
46.87% of the stock of Poseida Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Poseida Therapeutics are expected to decrease in the coming year, from ($1.77) to ($1.92) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Poseida Therapeutics is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Poseida Therapeutics is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Poseida Therapeutics has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Poseida Therapeutics Stock (NASDAQ:PSTX)

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.

PSTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PSTX Stock News Headlines

April 18, 2024 | prnewswire.com

Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

April 17, 2024 | finance.yahoo.com

Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 17, 2024 | prnewswire.com

Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus

April 16, 2024 | msn.com

Palisade Bio, Marinus Pharmaceuticals, Poseida Therapeutics among healthcare movers

April 10, 2024 | americanbankingnews.com

Poseida Therapeutics (NASDAQ:PSTX) versus BioNTech (NASDAQ:BNTX) Head to Head Comparison

April 10, 2024 | americanbankingnews.com

Comparing Poseida Therapeutics (NASDAQ:PSTX) and Fresh Tracks Therapeutics (NASDAQ:FRTX)

April 9, 2024 | investing.com

Poseida reports promising results for myeloma therapy

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 8, 2024 | prnewswire.com

Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma

April 1, 2024 | prnewswire.com

Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 26, 2024 | finanznachrichten.de

Poseida Therapeutics, Inc.: Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer

March 26, 2024 | msn.com

Poseida Therapeutics appoints Syed Rizvi as Chief Medical Officer

March 25, 2024 | finance.yahoo.com

Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer

March 19, 2024 | finance.yahoo.com

Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

March 15, 2024 | finance.yahoo.com

PSTX Apr 2024 5.000 put

March 15, 2024 | finanznachrichten.de

Poseida Therapeutics, Inc.: Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma

March 13, 2024 | finance.yahoo.com

Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma

March 13, 2024 | msn.com

Poseida spikes after FDA orphan status for CAR-T therapy

March 11, 2024 | msn.com

EQT, Genie Energy And Other Big Stocks Moving Lower On Monday

March 10, 2024 | finance.yahoo.com

US$14.00 - That's What Analysts Think Poseida Therapeutics, Inc. (NASDAQ:PSTX) Is Worth After These Results

March 9, 2024 | finance.yahoo.com

Poseida Therapeutics Full Year 2023 Earnings: Beats Expectations

March 8, 2024 | markets.businessinsider.com

Buy Rating for Poseida Therapeutics Amid Strong Financials and Promising Clinical Updates

March 8, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Poseida Therapeutics (PSTX), Lumos Pharma (LUMO)

March 8, 2024 | finance.yahoo.com

Poseida Therapeutics Inc (PSTX) Reports Fourth Quarter and Full Year 2023 Financial Results

March 8, 2024 | investorplace.com

PSTX Stock Earnings: Poseida Therapeutics Beats EPS, Beats Revenue for Q4 2023

March 7, 2024 | finance.yahoo.com

Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023

See More Headlines

Receive PSTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Poseida Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:PSTX
CUSIP: N/A
CIK: 1661460
Web: www.poseida.com
Phone: 858-779-3100
Fax: N/A
Employees: 330
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $14.67
High Stock Price Target: $20.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +626.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.39)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-123,430,000.00
Net Margins: -190.76%
Pretax Margin: -190.60%
Return on Equity: -94.90%
Return on Assets: -42.16%

Debt

Debt-to-Equity Ratio: 0.56
Current Ratio: 3.18
Quick Ratio: 3.18

Sales & Book Value

Annual Sales: $64.70 million
Price / Sales: 3.01
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.08 per share
Price / Book: 1.87

Miscellaneous

Outstanding Shares: 96,490,000
Free Float: 94,463,000
Market Cap: $194.91 million
Optionable: Optionable
Beta: 0.36

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Mr. Mark J. Gergen J.D. (Age 61)
Executive Chairman of the Board
Comp: $920.74k
Mr. Harry J. Leonhardt Esq. (Age 67)
J.D., General Counsel, Chief Compliance Officer & Corporate Secretary
Comp: $630.23k
Dr. Kristin Yarema Ph.D. (Age 52)
President, CEO & Director
Ms. Johanna M. Mylet CPA (Age 36)
Chief Financial Officer
Mr. Loren Wagner
Chief Operations Officer
Ms. Kristin Martin
Chief People & Administration Officer
Mr. Alexander Chapman
Senior VP of Investor Relations & Corporate Communications
Dr. Devon J. Shedlock Ph.D.
Chief Scientific Officer of Cell Therapy
Ms. Lisa Portale
Senior Vice President of Regulatory Affairs
Dr. Jeffrey W. Winkelman J.D.
Ph.D., Senior VP & Chief Patent Counsel

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

PSTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Poseida Therapeutics stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Poseida Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PSTX shares.
View PSTX analyst ratings or view top-rated stocks.
What is Poseida Therapeutics' stock price target for 2024?: 3 Wall Street research analysts have issued 12 month price targets for Poseida Therapeutics' stock. Their PSTX share price targets range from $10.00 to $20.00. On average, they expect the company's stock price to reach $14.67 in the next year. This suggests a possible upside of 626.1% from the stock's current price.
View analysts price targets for PSTX or view top-rated stocks among Wall Street analysts.
How have PSTX shares performed in 2024?: Poseida Therapeutics' stock was trading at $3.36 at the beginning of 2024. Since then, PSTX stock has decreased by 39.9% and is now trading at $2.02.
View the best growth stocks for 2024 here.
When is Poseida Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our PSTX earnings forecast.
How were Poseida Therapeutics' earnings last quarter?: Poseida Therapeutics, Inc. (NASDAQ:PSTX) released its earnings results on Thursday, March, 7th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.09. The firm earned $25 million during the quarter, compared to the consensus estimate of $12.50 million. Poseida Therapeutics had a negative trailing twelve-month return on equity of 94.90% and a negative net margin of 190.76%.

What ETFs hold Poseida Therapeutics' stock?: ETFs with the largest weight of Poseida Therapeutics (NASDAQ:PSTX) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA).Global X Genomics & Biotechnology ETF (GNOM).
What other stocks do shareholders of Poseida Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Poseida Therapeutics investors own include Moderna (MRNA), Advanced Micro Devices (AMD), AngloGold Ashanti (AU), Micron Technology (MU), Eaton (ETN), Corning (GLW), OPKO Health (OPK), Overstock.com (OSTK), Sorrento Therapeutics (SRNE) and SSR Mining (SSRM).
When did Poseida Therapeutics IPO?: Poseida Therapeutics (PSTX) raised $150 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. BofA Securities, Piper Sandler and William Blair acted as the underwriters for the IPO.
How do I buy shares of Poseida Therapeutics?: Shares of PSTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PSTX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Poseida Therapeutics (PSTX) Stock Price, News & Analysis

Poseida Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Poseida Therapeutics Stock (NASDAQ:PSTX)

PSTX Stock Price History

PSTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

PSTX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™